Pieris Pharmaceuticals Key Executives
This section highlights Pieris Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Pieris Pharmaceuticals
(Showing 0 of )
Pieris Pharmaceuticals Earnings
This section highlights Pieris Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2023 | 2023-05-10 | $-11.20 | $-14.40 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
$13.60
Stock Price
$17.96M
Market Cap
14
Employees
Boston, MA
Location
Financial Statements
Access annual & quarterly financial statements for Pieris Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $42.81M | $25.90M | $31.42M | $29.32M | $46.28M |
| Cost of Revenue | $41.80M | $2.78M | $2.37M | $46.53M | $55.00M |
| Gross Profit | $1.01M | $23.12M | $29.05M | $-17.21M | $-8.72M |
| Gross Profit Ratio | 2.40% | 89.27% | 92.50% | -58.68% | -18.84% |
| Research and Development Expenses | $41.80M | $52.98M | $66.66M | $46.53M | $55.00M |
| General and Administrative Expenses | $16.85M | $16.39M | $16.59M | $16.71M | $18.44M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $16.85M | $16.39M | $16.59M | $16.71M | $18.44M |
| Other Expenses | $13.91M | $-8.17M | $-3.69M | $-3.66M | $-26.00K |
| Operating Expenses | $72.57M | $61.20M | $79.56M | $63.24M | $73.44M |
| Cost and Expenses | $72.57M | $61.20M | $79.56M | $63.24M | $73.44M |
| Interest Income | $1.85M | $721.00K | $4.00K | $511.00K | $1.71M |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $1.78M | $2.78M | $2.37M | $2.13M | $1.04M |
| EBITDA | $-22.76M | $-30.50M | $-43.37M | $-31.61M | $-26.12M |
| EBITDA Ratio | -53.17% | -118.00% | -153.24% | -108.43% | -56.43% |
| Operating Income | $-29.76M | $-43.47M | $-51.83M | $-33.92M | $-27.16M |
| Operating Income Ratio | -69.51% | -167.84% | -164.97% | -115.68% | -58.68% |
| Total Other Income Expenses Net | $5.21M | $10.20M | $6.09M | $-3.15M | $1.69M |
| Income Before Tax | $-24.54M | $-33.28M | $-45.74M | $-37.07M | $-25.47M |
| Income Before Tax Ratio | -57.33% | -128.47% | -145.58% | -126.41% | -55.03% |
| Income Tax Expense | $- | $-2.02M | $-2.37M | $164.00K | $-1.71M |
| Net Income | $-24.54M | $-31.25M | $-43.37M | $-37.23M | $-23.75M |
| Net Income Ratio | -57.33% | -120.66% | -138.03% | -126.97% | -51.33% |
| EPS | $-21.80 | $-33.71 | $-53.75 | $-54.67 | $-37.54 |
| EPS Diluted | $-21.80 | $-33.71 | $-53.75 | $-54.67 | $-37.54 |
| Weighted Average Shares Outstanding | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K |
| Weighted Average Shares Outstanding Diluted | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $53.00K | $1.30M | $19.52M | $20.05M | $1.94M | $5.85M | $5.37M | $3.70M | $10.99M | $8.44M | $4.06M | $3.29M | $15.63M | $1.88M | $2.94M | $11.25M | $13.26M | $17.27M |
| Cost of Revenue | $- | $751.00K | $-30.00K | $4.45M | $739.00K | $725.00K | $571.00K | $585.00K | $772.00K | $11.95M | $840.00K | $588.00K | $18.94M | $15.80M | $16.56M | $10.62M | $11.82M | $11.33M | $12.76M | $14.12M |
| Gross Profit | $- | $-751.00K | $83.00K | $-3.15M | $18.78M | $19.33M | $1.36M | $5.26M | $4.60M | $-8.25M | $10.15M | $7.86M | $-14.88M | $-12.52M | $-929.00K | $-8.74M | $-8.88M | $-87.00K | $503.00K | $3.15M |
| Gross Profit Ratio | 0.00% | 0.00% | 156.60% | -242.90% | 96.20% | 96.40% | 70.50% | 90.00% | 85.60% | -223.10% | 92.40% | 93.00% | -366.80% | -381.00% | -5.90% | -465.69% | -302.25% | -0.77% | 3.79% | 18.26% |
| Research and Development Expenses | $-446.00K | $751.00K | $1.25M | $4.45M | $9.60M | $14.33M | $13.42M | $13.38M | $13.59M | $11.95M | $14.07M | $15.36M | $18.94M | $15.80M | $16.56M | $10.62M | $11.82M | $11.33M | $12.76M | $14.12M |
| General and Administrative Expenses | $3.58M | $3.43M | $4.14M | $2.33M | $6.84M | $3.66M | $4.02M | $3.98M | $3.95M | $4.08M | $4.38M | $4.08M | $4.13M | $4.25M | $4.13M | $3.67M | $4.12M | $4.57M | $4.36M | $4.48M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.58M | $3.43M | $4.14M | $2.33M | $6.84M | $3.66M | $4.02M | $3.98M | $3.95M | $4.08M | $4.38M | $4.08M | $4.13M | $4.25M | $4.13M | $3.67M | $4.12M | $4.57M | $4.36M | $4.48M |
| Other Expenses | $- | $- | $171.00K | $15.60M | $506.00K | $-161.00K | $-2.03M | $-3.39M | $-1.47M | $676.00K | $-2.13M | $-1.09M | $678.00K | $464.00K | $884.00K | $-1.83M | $-1.34M | $-424.00K | $-60.00K | $177.00K |
| Operating Expenses | $3.13M | $4.18M | $5.39M | $6.78M | $16.43M | $16.41M | $15.42M | $13.97M | $16.07M | $14.84M | $16.32M | $18.35M | $21.27M | $19.25M | $20.69M | $14.29M | $15.94M | $15.90M | $17.12M | $18.60M |
| Cost and Expenses | $3.13M | $4.18M | $5.36M | $6.78M | $16.43M | $16.41M | $15.42M | $13.97M | $16.07M | $14.84M | $16.32M | $18.35M | $21.27M | $19.25M | $20.69M | $14.29M | $15.94M | $15.90M | $17.12M | $18.60M |
| Interest Income | $169.00K | $201.00K | $240.00K | $455.00K | $549.00K | $490.00K | $357.00K | $351.00K | $241.00K | $132.00K | $- | $- | $4.00K | $3.00K | $3.00K | $8.00K | $55.00K | $129.00K | $319.00K | $382.00K |
| Interest Expense | $- | $- | $- | $2.33M | $- | $- | $- | $- | $241.00K | $- | $3.00K | $6.00K | $- | $- | $- | $1.82M | $1.28M | $295.00K | $- | $- |
| Depreciation and Amortization | $- | $-1 | $-30.00K | $476.00K | $739.00K | $725.00K | $571.00K | $585.00K | $772.00K | $573.00K | $840.00K | $588.00K | $586.00K | $594.00K | $600.00K | $607.00K | $495.00K | $487.00K | $538.00K | $673.00K |
| EBITDA | $-3.13M | $-4.18M | $-5.30M | $-4.58M | $3.83M | $4.70M | $-12.61M | $-7.52M | $-8.96M | $-9.77M | $-4.26M | $-9.28M | $-15.95M | $-14.90M | $-4.43M | $-11.72M | $-12.24M | $-4.17M | $-3.32M | $-657.00K |
| EBITDA Ratio | 0.00% | 0.00% | -10006.00% | -353.00% | 20.00% | 23.00% | -651.00% | -139.04% | -199.26% | -285.64% | -38.75% | -117.30% | -409.96% | -467.91% | -28.52% | -628.88% | -425.45% | -37.06% | -25.02% | -3.80% |
| Operating Income | $-3.13M | $-4.18M | $-5.30M | $-5.48M | $-11.81M | $2.06M | $-15.51M | $-11.52M | $-12.17M | $-12.33M | $-7.46M | $-11.00M | $-19.01M | $-16.76M | $-5.06M | $-12.41M | $-13.00M | $-4.66M | $-3.86M | $-1.33M |
| Operating Income Ratio | 0.00% | 0.00% | -10005.66% | -422.02% | -60.49% | 10.29% | -801.19% | -197.04% | -226.59% | -333.42% | -67.86% | -130.27% | -468.62% | -510.23% | -32.36% | -661.21% | -442.29% | -41.39% | -29.08% | -7.70% |
| Total Other Income Expenses Net | $248.00K | $587.00K | $411.00K | $-83.00K | $1.05M | $1.91M | $2.33M | $3.42M | $2.43M | $1.99M | $2.36M | $1.47M | $2.48M | $1.26M | $887.00K | $-1.82M | $-1.28M | $-295.00K | $259.00K | $559.00K |
| Income Before Tax | $-2.89M | $-3.59M | $-4.89M | $-4.58M | $-10.75M | $3.98M | $-13.18M | $-8.10M | $-9.74M | $-10.34M | $-5.10M | $-9.53M | $-16.54M | $-15.50M | $-4.17M | $-14.24M | $-14.28M | $-4.95M | $-3.60M | $-771.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | -9230.19% | -352.89% | -55.08% | 19.83% | -680.94% | -138.59% | -181.30% | -279.56% | -46.42% | -112.90% | -407.59% | -471.78% | -26.69% | -758.44% | -485.98% | -44.02% | -27.12% | -4.46% |
| Income Tax Expense | $- | $- | $-73.28K | $-699.00K | $14.34M | $-490.00K | $-871.00K | $-26.00K | $-1.21M | $-132.00K | $-2.36M | $-372.00K | $-682.00K | $-467.00K | $-887.00K | $1.99M | $1.28M | $295.00K | $-259.00K | $-559.00K |
| Net Income | $-2.89M | $-3.59M | $-4.89M | $-4.58M | $-10.75M | $3.98M | $-12.31M | $-8.08M | $-8.53M | $-10.34M | $-2.75M | $-9.16M | $-16.54M | $-15.50M | $-4.17M | $-14.40M | $-14.28M | $-4.95M | $-3.60M | $-771.00K |
| Net Income Ratio | 0.00% | 0.00% | -9230.19% | -352.89% | -55.08% | 19.83% | -635.95% | -138.15% | -158.86% | -279.56% | -24.98% | -108.49% | -407.59% | -471.78% | -26.69% | -767.18% | -485.98% | -44.02% | -27.12% | -4.46% |
| EPS | $-2.19 | $-2.76 | $-3.95 | $-3.71 | $-8.70 | $3.63 | $-13.22 | $-8.68 | $-9.17 | $-0.14 | $-2.98 | $-10.16 | $-19.53 | $-20.03 | $-5.93 | $-20.57 | $-21.03 | $-7.56 | $-5.21 | $-1.16 |
| EPS Diluted | $-2.19 | $-2.76 | $-3.95 | $-3.71 | $-8.70 | $3.63 | $-13.22 | $-8.68 | $-9.17 | $-0.14 | $-2.98 | $-10.16 | $-19.53 | $-20.03 | $-5.93 | $-20.57 | $-21.03 | $-7.56 | $-5.21 | $-1.16 |
| Weighted Average Shares Outstanding | 1.32M | 1.30M | 1.24M | 1.24M | 1.24M | 1.10M | 931.49K | 930.60K | 929.96K | 74.12M | 921.39K | 901.64K | 846.62K | 773.81K | 703.71K | 699.95K | 679.25K | 654.64K | 690.15K | 663.56K |
| Weighted Average Shares Outstanding Diluted | 1.32M | 1.30M | 1.24M | 1.24M | 1.24M | 1.10M | 931.49K | 930.60K | 929.96K | 74.12M | 921.39K | 901.64K | 846.62K | 773.81K | 703.71K | 699.95K | 679.25K | 654.64K | 690.15K | 663.56K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $17.40M | $38.63M | $117.76M | $70.44M | $62.26M |
| Short Term Investments | $8.97M | $20.53M | $- | $- | $41.89M |
| Cash and Short Term Investments | $26.37M | $59.17M | $117.76M | $70.44M | $104.15M |
| Net Receivables | $572.00K | $5.81M | $3.31M | $1.71M | $6.79M |
| Inventory | $- | $- | $- | $1 | $- |
| Other Current Assets | $11.74M | $8.45M | $13.10M | $7.16M | $8.14M |
| Total Current Assets | $38.68M | $73.42M | $127.62M | $75.72M | $115.01M |
| Property Plant Equipment Net | $- | $20.70M | $23.03M | $25.98M | $22.94M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $1.37M | $2.90M | $3.31M | $3.15M |
| Total Non-Current Assets | $- | $22.07M | $25.93M | $29.29M | $26.08M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $38.68M | $95.49M | $153.56M | $105.01M | $141.10M |
| Account Payables | $3.37M | $4.15M | $8.61M | $1.79M | $5.80M |
| Short Term Debt | $- | $859.00K | $1.05M | $1.03M | $733.00K |
| Tax Payables | $- | $- | $- | $128.00K | $522.00K |
| Deferred Revenue | $- | $20.82M | $25.12M | $12.63M | $11.26M |
| Other Current Liabilities | $8.55M | $10.75M | $15.79M | $6.57M | $8.69M |
| Total Current Liabilities | $11.92M | $36.58M | $50.56M | $22.14M | $27.00M |
| Long Term Debt | $- | $12.24M | $13.84M | $15.93M | $15.48M |
| Deferred Revenue Non-Current | $- | $18.73M | $38.40M | $35.90M | $47.26M |
| Deferred Tax Liabilities Non-Current | $- | $-18.73M | $-38.40M | $- | $-47.26M |
| Other Non-Current Liabilities | $- | $- | $- | $6.00K | $- |
| Total Non-Current Liabilities | $- | $30.98M | $52.24M | $51.84M | $62.74M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $11.92M | $67.56M | $102.81M | $73.98M | $89.75M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $98.00K | $74.00K | $72.00K | $56.00K | $55.00K |
| Retained Earnings | $-314.96M | $-290.42M | $-257.14M | $-211.41M | $-174.18M |
| Accumulated Other Comprehensive Income Loss | $28.00K | $-254.00K | $829.00K | $-295.00K | $-2.00M |
| Other Total Stockholders Equity | $341.60M | $318.53M | $307.00M | $242.67M | $227.47M |
| Total Stockholders Equity | $26.76M | $27.93M | $50.76M | $31.03M | $51.35M |
| Total Equity | $26.76M | $27.93M | $50.76M | $31.03M | $51.35M |
| Total Liabilities and Stockholders Equity | $38.68M | $95.49M | $153.56M | $105.01M | $141.10M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $38.68M | $95.49M | $153.56M | $105.01M | $141.10M |
| Total Investments | $8.97M | $20.53M | $- | $- | $41.89M |
| Total Debt | $- | $13.10M | $13.84M | $16.96M | $16.22M |
| Net Debt | $-17.40M | $-25.53M | $-103.92M | $-53.47M | $-46.04M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $19.36M | $19.73M | $19.08M | $17.40M | $32.89M | $44.94M | $39.74M | $38.63M | $48.42M | $54.26M | $83.74M | $117.76M | $125.05M | $119.10M | $66.83M | $70.44M | $66.89M | $44.30M | $47.43M | $62.26M |
| Short Term Investments | $- | $- | $- | $8.97M | $11.92M | $9.94M | $8.64M | $20.53M | $21.40M | $26.68M | $16.53M | $- | $- | $- | $- | $- | $15.75M | $32.91M | $39.33M | $41.89M |
| Cash and Short Term Investments | $19.36M | $19.73M | $19.08M | $26.37M | $44.81M | $54.88M | $48.38M | $59.17M | $69.82M | $80.94M | $100.27M | $117.76M | $125.05M | $119.10M | $66.83M | $70.44M | $82.64M | $77.21M | $86.76M | $104.15M |
| Net Receivables | $879.00K | $4.67M | $7.25M | $2.90M | $1.04M | $952.00K | $1.05M | $5.81M | $829.00K | $1.26M | $1.64M | $3.31M | $6.65M | $2.80M | $15.81M | $1.71M | $2.94M | $10.71M | $7.27M | $6.79M |
| Inventory | $- | $- | $- | $- | $2.10M | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $1 | $1 | $- | $- | $- | $- |
| Other Current Assets | $280.00K | $649.00K | $3.17M | $11.74M | $22.39M | $10.64M | $11.07M | $8.45M | $15.82M | $17.41M | $19.67M | $13.10M | $11.90M | $11.55M | $11.25M | $7.16M | $6.15M | $8.20M | $8.68M | $8.14M |
| Total Current Assets | $20.52M | $25.05M | $29.50M | $38.68M | $59.09M | $66.47M | $60.51M | $73.42M | $78.56M | $90.90M | $111.75M | $127.62M | $137.65M | $127.67M | $88.27M | $75.72M | $88.66M | $92.03M | $98.37M | $115.01M |
| Property Plant Equipment Net | $- | $- | $196.00K | $- | $1.98M | $19.98M | $20.50M | $20.70M | $19.30M | $21.05M | $22.69M | $23.03M | $23.59M | $24.23M | $24.30M | $25.98M | $25.07M | $23.78M | $23.51M | $22.94M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.81M | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $- | $-1.70M | $1.09M | $1.25M | $1.37M | $1.31M | $2.36M | $2.67M | $2.90M | $1.14M | $3.12M | $3.21M | $3.31M | $1.99M | $1.98M | $1.89M | $3.15M |
| Total Non-Current Assets | $- | $- | $196.00K | $- | $287.00K | $21.07M | $21.75M | $22.07M | $20.60M | $23.41M | $25.37M | $25.93M | $26.54M | $27.36M | $27.51M | $29.29M | $27.07M | $25.75M | $25.40M | $26.08M |
| Other Assets | $- | $- | $-196.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $20.52M | $25.05M | $29.50M | $38.68M | $59.38M | $87.54M | $82.26M | $95.49M | $99.16M | $114.31M | $137.12M | $153.56M | $164.18M | $155.03M | $115.79M | $105.01M | $115.72M | $117.78M | $123.77M | $141.10M |
| Account Payables | $801.00K | $969.00K | $1.52M | $3.37M | $2.82M | $7.60M | $5.83M | $4.15M | $3.64M | $1.90M | $4.50M | $8.61M | $3.56M | $2.31M | $3.47M | $1.79M | $2.15M | $4.41M | $3.50M | $5.80M |
| Short Term Debt | $- | $- | $- | $- | $24.58M | $910.00K | $890.00K | $859.00K | $826.00K | $914.00K | $1.00M | $1.05M | $1.03M | $959.00K | $987.00K | $1.03M | $934.00K | $881.00K | $851.00K | $733.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $429.00K | $128.00K | $126.00K | $69.00K | $444.00K | $522.00K |
| Deferred Revenue | $- | $- | $- | $- | $994.00K | $17.68M | $26.69M | $20.82M | $18.50M | $22.86M | $20.91M | $25.12M | $26.45M | $25.54M | $17.24M | $12.63M | $10.04M | $7.91M | $10.04M | $11.26M |
| Other Current Liabilities | $3.45M | $5.38M | $6.01M | $8.55M | $472.00K | $8.17M | $9.46M | $10.75M | $10.56M | $9.87M | $13.07M | $15.79M | $18.65M | $15.12M | $8.15M | $6.57M | $6.43M | $4.99M | $5.64M | $8.69M |
| Total Current Liabilities | $4.25M | $6.35M | $7.53M | $11.92M | $28.87M | $34.37M | $42.88M | $36.58M | $33.52M | $35.55M | $39.48M | $50.56M | $49.70M | $43.93M | $30.27M | $22.14M | $19.69M | $18.26M | $20.48M | $27.00M |
| Long Term Debt | $- | $- | $- | $- | $- | $11.92M | $12.20M | $12.24M | $11.39M | $12.34M | $13.36M | $13.84M | $14.45M | $14.96M | $14.97M | $15.93M | $15.43M | $15.01M | $14.92M | $15.48M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $759.00K | $11.73M | $18.73M | $18.48M | $22.06M | $30.82M | $38.40M | $46.19M | $49.42M | $32.31M | $35.90M | $36.92M | $37.84M | $38.56M | $47.26M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $-759.00K | $-11.73M | $-18.73M | $-18.48M | $-22.06M | $-30.82M | $-38.40M | $-46.19M | $-49.42M | $-32.31M | $- | $-36.92M | $-37.84M | $-38.56M | $-47.26M |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.00K | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $12.68M | $23.93M | $30.98M | $29.88M | $34.40M | $44.18M | $52.24M | $60.63M | $64.38M | $47.28M | $51.84M | $52.35M | $52.85M | $53.48M | $62.74M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $4.25M | $6.35M | $7.53M | $11.92M | $28.87M | $47.05M | $66.80M | $67.56M | $63.40M | $69.94M | $83.67M | $102.81M | $110.33M | $108.31M | $77.55M | $73.98M | $72.03M | $71.11M | $73.97M | $89.75M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $98.00K | $99.00K | $99.00K | $74.00K | $74.00K | $74.00K | $74.00K | $74.00K | $72.00K | $72.00K | $67.00K | $60.00K | $56.00K | $56.00K | $52.00K | $55.00K | $55.00K |
| Retained Earnings | $-326.33M | $-323.45M | $-319.86M | $-314.96M | $-310.38M | $-299.63M | $-303.60M | $-290.42M | $-282.32M | $-272.58M | $-262.25M | $-257.14M | $-247.61M | $-231.08M | $-215.58M | $-211.41M | $-197.01M | $-182.72M | $-177.77M | $-174.18M |
| Accumulated Other Comprehensive Income Loss | $-316.00K | $-436.00K | $-346.00K | $28.00K | $-339.00K | $-137.00K | $-426.00K | $-254.00K | $524.00K | $625.00K | $953.00K | $829.00K | $616.00K | $234.00K | $194.00K | $-295.00K | $-782.00K | $-1.06M | $-1.23M | $-2.00M |
| Other Total Stockholders Equity | $342.92M | $342.59M | $342.17M | $341.60M | $341.13M | $340.16M | $319.41M | $318.53M | $317.49M | $316.25M | $314.67M | $307.00M | $300.78M | $277.50M | $253.56M | $242.67M | $241.42M | $230.41M | $228.75M | $227.47M |
| Total Stockholders Equity | $16.27M | $18.70M | $21.96M | $26.76M | $30.51M | $40.50M | $15.46M | $27.93M | $35.77M | $44.37M | $53.45M | $50.76M | $53.85M | $46.72M | $38.24M | $31.03M | $43.69M | $46.67M | $49.81M | $51.35M |
| Total Equity | $16.27M | $18.70M | $21.96M | $26.76M | $30.51M | $40.50M | $15.46M | $27.93M | $35.77M | $44.37M | $53.45M | $50.76M | $53.85M | $46.72M | $38.24M | $31.03M | $43.69M | $46.67M | $49.81M | $51.35M |
| Total Liabilities and Stockholders Equity | $20.52M | $25.05M | $29.50M | $38.68M | $59.38M | $87.54M | $82.26M | $95.49M | $99.16M | $114.31M | $137.12M | $153.56M | $164.18M | $155.03M | $115.79M | $105.01M | $115.72M | $117.78M | $123.77M | $141.10M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $20.52M | $25.05M | $29.50M | $38.68M | $59.38M | $87.54M | $82.26M | $95.49M | $99.16M | $114.31M | $137.12M | $153.56M | $164.18M | $155.03M | $115.79M | $105.01M | $115.72M | $117.78M | $123.77M | $141.10M |
| Total Investments | $- | $- | $- | $8.97M | $11.92M | $9.94M | $8.64M | $20.53M | $21.40M | $26.68M | $16.53M | $- | $1.81M | $- | $- | $- | $15.75M | $32.91M | $39.33M | $41.89M |
| Total Debt | $- | $- | $- | $- | $12.29M | $12.83M | $12.20M | $13.10M | $12.22M | $13.25M | $14.37M | $14.89M | $15.48M | $15.92M | $15.96M | $16.96M | $16.36M | $15.89M | $15.78M | $16.22M |
| Net Debt | $-19.36M | $-19.73M | $-19.08M | $-17.40M | $-20.60M | $-32.11M | $-27.54M | $-25.53M | $-36.21M | $-41.01M | $-69.37M | $-102.87M | $-109.58M | $-103.18M | $-50.88M | $-53.47M | $-50.53M | $-28.41M | $-31.66M | $-46.04M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-24.54M | $-33.28M | $-45.74M | $-37.23M | $-25.47M |
| Depreciation and Amortization | $1.78M | $2.78M | $2.37M | $2.13M | $1.04M |
| Deferred Income Tax | $-4.52M | $- | $- | $164.00K | $-1.22M |
| Stock Based Compensation | $3.35M | $4.40M | $5.21M | $5.09M | $5.37M |
| Change in Working Capital | $-7.38M | $-33.37M | $30.52M | $-16.38M | $-32.12M |
| Accounts Receivables | $5.31M | $-2.62M | $-1.81M | $5.34M | $-4.05M |
| Inventory | $- | $- | $5.73M | $-2.87M | $-799.00K |
| Accounts Payables | $-789.00K | $-4.21M | $7.05M | $-4.35M | $1.26M |
| Other Working Capital | $-11.90M | $-26.54M | $19.55M | $-14.50M | $-28.52M |
| Other Non Cash Items | $-22.50M | $-467.00K | $-30.00K | $330.00K | $-69.00K |
| Net Cash Provided by Operating Activities | $-53.82M | $-59.93M | $-7.66M | $-45.90M | $-52.47M |
| Investments in Property Plant and Equipment | $-171.00K | $-1.04M | $-949.00K | $-2.73M | $-2.46M |
| Acquisitions Net | $-12.17M | $20.20M | $- | $-41.94M | $-12.30M |
| Purchases of Investments | $-22.84M | $-48.40M | $- | $-41.50M | $-59.32M |
| Sales Maturities of Investments | $35.01M | $28.20M | $- | $83.44M | $71.62M |
| Other Investing Activities | $12.17M | $-20.20M | $- | $41.94M | $12.30M |
| Net Cash Used for Investing Activities | $12.00M | $-21.24M | $-949.00K | $39.21M | $9.84M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $19.80M | $6.92M | $57.10M | $9.62M | $31.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $19.80M | $292.00K | $2.03M | $491.00K | $1.17M |
| Net Cash Used Provided by Financing Activities | $19.80M | $7.21M | $59.13M | $10.12M | $32.17M |
| Effect of Forex Changes on Cash | $783.00K | $-5.17M | $-3.19M | $4.75M | $-2.14M |
| Net Change in Cash | $-21.24M | $-79.13M | $47.33M | $8.18M | $-12.61M |
| Cash at End of Period | $17.40M | $38.63M | $117.76M | $70.44M | $62.26M |
| Cash at Beginning of Period | $38.63M | $117.76M | $70.44M | $62.26M | $74.87M |
| Operating Cash Flow | $-53.82M | $-59.93M | $-7.66M | $-45.90M | $-52.47M |
| Capital Expenditure | $-171.00K | $-1.04M | $-949.00K | $-2.73M | $-2.46M |
| Free Cash Flow | $-53.99M | $-60.97M | $-8.61M | $-48.62M | $-54.93M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.89M | $-3.59M | $-4.89M | $-4.58M | $-10.75M | $3.98M | $-13.18M | $-8.10M | $-9.74M | $-10.34M | $-5.10M | $-9.53M | $-16.54M | $-15.50M | $-4.17M | $-14.40M | $-14.28M | $-4.95M | $-3.60M | $-771.00K |
| Depreciation and Amortization | $- | $- | $-30.00K | $-198.00K | $708.00K | $725.00K | $571.00K | $585.00K | $772.00K | $583.00K | $840.00K | $588.00K | $586.00K | $594.00K | $600.00K | $607.00K | $495.00K | $487.00K | $538.00K | $673.00K |
| Deferred Income Tax | $- | $- | $- | $-253.00K | $14.89M | $-106.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $164.00K | $- | $- | $- | $-1.22M |
| Stock Based Compensation | $330.00K | $421.00K | $472.00K | $451.00K | $966.00K | $1.05M | $884.00K | $949.00K | $974.00K | $1.30M | $1.18M | $1.32M | $1.37M | $1.33M | $1.20M | $1.17M | $1.40M | $1.24M | $1.28M | $1.11M |
| Change in Working Capital | $1.77M | $2.19M | $-3.96M | $-14.34M | $-15.52M | $-18.89M | $607.00K | $-5.98M | $-451.00K | $-7.29M | $-19.65M | $-3.26M | $56.00K | $43.46M | $-9.72M | $-1.58M | $5.46M | $-6.79M | $-13.46M | $-12.76M |
| Accounts Receivables | $- | $- | $- | $5.31M | $- | $- | $- | $-2.62M | $- | $- | $- | $-1.81M | $- | $- | $- | $5.34M | $- | $- | $- | $-4.05M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-18.22M | $- | $- | $- | $-989.00K | $- | $- | $- | $2.80M |
| Accounts Payables | $- | $- | $- | $-805.00K | $- | $- | $16.00K | $-4.21M | $- | $- | $298.00K | $7.05M | $- | $- | $36.00K | $-4.35M | $- | $- | $590.00K | $1.26M |
| Other Working Capital | $1.77M | $2.19M | $-3.41M | $21.11M | $-15.52M | $-18.89M | $591.00K | $851.00K | $-451.00K | $-7.29M | $-19.95M | $9.72M | $56.00K | $43.46M | $-9.76M | $-1.58M | $5.46M | $-6.79M | $-14.04M | $-12.76M |
| Other Non Cash Items | $932.00K | $-503.00K | $1.83M | $-748.00K | $-19.00K | $-182.00K | $125.00K | $-384.00K | $-337.00K | $123.00K | $91.00K | $-56.00K | $40.00K | $27.00K | $-41.00K | $623.00K | $-636.00K | $243.00K | $100.00K | $-1.01M |
| Net Cash Provided by Operating Activities | $146.00K | $-1.48M | $-7.00M | $-19.67M | $-9.72M | $-13.43M | $-11.00M | $-12.93M | $-8.78M | $-15.58M | $-22.64M | $-10.94M | $-14.48M | $29.91M | $-12.14M | $-13.42M | $-7.57M | $-9.78M | $-15.13M | $-13.97M |
| Investments in Property Plant and Equipment | $- | $- | $- | $13.00K | $-69.00K | $-67.00K | $-48.00K | $-1.01M | $-34.00K | $-629.00K | $-389.00K | $-342.00K | $-350.00K | $-229.00K | $-28.00K | $-578.00K | $840.00K | $-1.06M | $-1.93M | $-1.18M |
| Acquisitions Net | $- | $- | $- | $-3.44M | $1.92M | $1.30M | $-11.95M | $- | $-5.50M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $-7.57M | $-7.03M | $-6.70M | $-1.54M | $-5.20M | $-11.55M | $-15.09M | $-16.56M | $- | $- | $- | $- | $-321.00K | $-2.65M | $-12.49M | $-26.03M | $-10.55M |
| Sales Maturities of Investments | $-2.18M | $2.18M | $9.00M | $11.00M | $5.11M | $5.40M | $13.49M | $6.30M | $17.05M | $4.85M | $- | $- | $- | $- | $- | $15.75M | $20.16M | $19.15M | $28.37M | $9.85M |
| Other Investing Activities | $2.32M | $- | $9.00M | $3.44M | $-1.92M | $-1.30M | $11.95M | $1.02M | $5.50M | $-10.24M | $-16.56M | $- | $- | $- | $- | $15.43M | $17.51M | $6.66M | $2.34M | $-705.00K |
| Net Cash Used for Investing Activities | $142.00K | $2.18M | $9.00M | $3.45M | $-1.98M | $-1.37M | $11.90M | $1.11M | $5.47M | $-10.87M | $-16.95M | $-342.00K | $-350.00K | $-229.00K | $-28.00K | $14.85M | $18.35M | $5.60M | $414.00K | $-1.88M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $14.00K | $- | $19.73M | $- | $93.00K | $282.00K | $167.00K | $6.47M | $4.67M | $21.35M | $21.41M | $9.67M | $9.62M | $9.62M | $- | $- | $31.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.73M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $14.00K | $- | $52.00K | $- | $93.00K | $- | $114.00K | $85.00K | $235.00K | $566.00K | $1.21M | $20.00K | $75.00K | $- | $416.00K | $- | $667.00K |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $14.00K | $- | $19.78M | $- | $93.00K | $282.00K | $281.00K | $6.56M | $4.90M | $21.92M | $22.62M | $9.69M | $75.00K | $9.62M | $416.00K | $- | $31.66M |
| Effect of Forex Changes on Cash | $-656.00K | $-49.00K | $-316.00K | $708.00K | $-337.00K | $212.00K | $200.00K | $1.95M | $-2.81M | $-3.32M | $-994.00K | $-903.00K | $-1.13M | $-32.00K | $-1.13M | $2.04M | $2.18M | $637.00K | $-112.00K | $382.00K |
| Net Change in Cash | $-368.00K | $647.00K | $1.69M | $-15.50M | $-12.04M | $5.20M | $1.11M | $-9.79M | $-5.83M | $-29.48M | $-34.03M | $-7.29M | $5.96M | $52.26M | $-3.60M | $3.55M | $22.59M | $-3.13M | $-14.83M | $16.19M |
| Cash at End of Period | $19.36M | $19.73M | $19.08M | $17.40M | $32.89M | $44.94M | $39.74M | $38.63M | $48.42M | $54.26M | $83.74M | $117.76M | $125.05M | $119.10M | $66.83M | $70.44M | $66.89M | $44.30M | $47.43M | $62.26M |
| Cash at Beginning of Period | $19.73M | $19.08M | $17.40M | $32.89M | $44.94M | $39.74M | $38.63M | $48.42M | $54.26M | $83.74M | $117.76M | $125.05M | $119.10M | $66.83M | $70.44M | $66.89M | $44.30M | $47.43M | $62.26M | $46.07M |
| Operating Cash Flow | $146.00K | $-1.48M | $-7.00M | $-19.67M | $-9.72M | $-13.43M | $-11.00M | $-12.93M | $-8.78M | $-15.58M | $-22.64M | $-10.94M | $-14.48M | $29.91M | $-12.14M | $-13.42M | $-7.57M | $-9.78M | $-15.13M | $-13.97M |
| Capital Expenditure | $- | $- | $- | $13.00K | $-69.00K | $-67.00K | $-48.00K | $-1.01M | $-34.00K | $-629.00K | $-389.00K | $-342.00K | $-350.00K | $-229.00K | $-28.00K | $-578.00K | $840.00K | $-1.06M | $-1.93M | $-1.18M |
| Free Cash Flow | $146.00K | $-1.48M | $-7.00M | $-19.66M | $-9.79M | $-13.50M | $-11.04M | $-13.94M | $-8.81M | $-16.21M | $-23.03M | $-11.29M | $-14.83M | $29.68M | $-12.17M | $-13.99M | $-6.73M | $-10.84M | $-17.06M | $-15.15M |
Pieris Pharmaceuticals Dividends
Explore Pieris Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Pieris Pharmaceuticals News
Read the latest news about Pieris Pharmaceuticals, including recent articles, headlines, and updates.
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) (the “Company”) and Palvella Therapeutics, Inc. Upon completion of the proposed transaction, Pieris shareholders are expected to own approximately 18% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequ.
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. Halper Sadeh encourages Pieris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halper.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
NEW YORK , Aug. 16, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceutical s , Inc. ( Nasdaq : PIRS ) , relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol "PIRS".
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® (antibody-Anticalin fusion) protein immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. After considering an extensive range of options, the Company's Board of Directors decided to implement this new strategy along with relevant cost-saving measures that are expected to extend the Company's cash runway into 2027.
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored phase 1/2 study of BOS-342 (formerly PRS-342), a 4-1BB/GPC3 immuno-oncology antibody-Anticalin fusion (Mabcalin™) bispecific protein, which was discovered by Pieris and licensed to Boston Pharmaceuticals and designed to provide a potent costimulatory bridge to exert tumor killing activity through the recruitment of T-cells.
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today provided a strategic update following recent events that have impacted its inhaled respiratory franchise, including AstraZeneca's discontinuation of enrollment of the Phase 2a study for elarekibep. AstraZeneca has now informed the Company of its decision to terminate the parties' R&D collaboration agreement and hand back elarekibep along with discontinuing the remaining discovery program.
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, president and chief executive officer of Pieris, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York City.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PIRS.